A study published in Scientific Reports investigated the relationship between periodontitis and fatty liver disease. The findings show that signs of periodontal disease, including a periodontal pocket depth greater than 6 mm and gingival bleeding, are associated with fatty liver disease and a greater degree of liver fibrosis.
Vitamin D plays an important role in fatty liver disease, including in patients with normal body weight. Recent research suggests that maintaining adequate vitamin D levels may improve liver health and metabolic parameters in affected individuals.
Fatty liver and hepatitis B can coexist and worsen liver damage. Combined treatment helps reduce inflammation, fibrosis, and disease progression.
Metabolic syndrome increases the risk of bile duct cancer, especially in patients with fatty liver, where liver disease tends to be more aggressive.
A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.
A study shows that eating fewer than three times a day and fasting over 14 hours increases fatty liver risk due to circadian rhythm disruption.
A study published analyzes the effectiveness of a low-carbohydrate diet in patients with fatty liver disease. Results show weight loss, reduced abdominal circumference, and improvements in liver inflammation and glucose metabolism.
HU6 is a novel oral drug that reduces liver fat and body weight through controlled metabolic acceleration, showing promising results in clinical trials compared to placebo.
A large study shows that daily alcohol consumption, even in small amounts, worsens liver fibrosis in patients with metabolic liver disease.
A large study reveals that vitamin E can reduce liver fibrosis and improve liver health in patients, reinforcing its therapeutic value alongside diet and exercise.